The latest announcement is out from Celularity (CELU).
Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, filling a vacancy created by the resignation of Robin L. Smith, M.D. Berman, considered independent according to Nasdaq’s standards, will also join the Audit Committee. He’s granted an option to buy 118,111 shares of Celularity’s stock, vesting over three years with continued service, and has entered into a standard indemnification agreement with the company. Additionally, following Marc Mazur’s departure, Celularity’s board will reduce from seven to six directors.
For a thorough assessment of CELU stock, go to TipRanks’ Stock Analysis page.
